ASHAP – an effective salvage therapy for recurrent and refractory malignant lymphomas

[1]  F. Cabanillas,et al.  Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. , 1997, Hematology/oncology clinics of North America.

[2]  R. Lifton,et al.  Autotransplantation for relapsed or refractory non-Hodgkin’s lymphoma (NHL): long-term follow-up and analysis of prognostic factors , 1997, Bone Marrow Transplantation.

[3]  R. Marcus,et al.  High-dose therapy and autologous stem cell rescue for poor risk and refractory lymphoma: a single centre experience of 123 patients. , 1996, Bone marrow transplantation.

[4]  R. Tsang,et al.  The Role of Intensive Therapy and Autologous Blood and Marrow Transplantation for Chemotherapy‐Sensitive Relapsed and Primary Refractory Non‐Hodgkin’s Lymphoma: Identification of Major Prognostic Groups , 1996, British journal of haematology.

[5]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[6]  B. Littenberg,et al.  Autologous bone marrrow transplantation versus chemotherapy in relapsed/refractory non‐hodgkin's lymphoma: Estimates of long‐term survival from the recent literatur , 1995 .

[7]  W. Velasquez,et al.  Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  W. Velasquez,et al.  A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  B. Littenberg,et al.  Autologous bone marrow transplantation versus chemotherapy in relapsed/refractory non-Hodgkin's lymphoma: estimates of long-term survival from the recent literature. , 1995, American journal of hematology.

[10]  S. Tucker,et al.  ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Raja,et al.  E-SHAP: an effective treatment in selected patients with relapsed non-Hodgkin's lymphoma. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  N. Schmitz,et al.  Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. A. Tanner,et al.  One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Armitage,et al.  High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  W. Wilson,et al.  EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Strawderman,et al.  Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Winfield,et al.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial , 1993, The Lancet.

[18]  F. Mandelli,et al.  Granulocyte colony stimulating factor (G-CSF) as adjunct therapy in relapsed-resistant high-grade non-Hodgkin's lymphoma. , 1993, Haematologica.

[19]  B. Coiffier,et al.  Autologous hematopoietic stem cell transplantation in intermediate and high grade non-Hodgkin's lymphoma: a review. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  B. Coiffier,et al.  Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Linch,et al.  Mini‐BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease , 1992, British journal of haematology.

[22]  B. Hillner,et al.  The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  E. Jaffe,et al.  Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Bates,et al.  P‐glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines , 1991, International journal of cancer.

[25]  F. Appelbaum,et al.  Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Sutcliffe,et al.  Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease. , 1990, Bone marrow transplantation.

[27]  S. Jagannath,et al.  Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). , 1988, Blood.

[28]  S. Jagannath,et al.  Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. , 1988, Seminars in hematology.

[29]  V. Diehl,et al.  Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group. , 1987, Cancer treatment reports.

[30]  J. Armitage,et al.  High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. , 1987, The New England journal of medicine.

[31]  G. Fillet,et al.  [Treatment of non-Hodgkin's lymphoma]. , 1987, Revue medicale de Liege.

[32]  W. Velasquez,et al.  Results of MIME salvage regimen for recurrent or refractory lymphoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Dumont,et al.  Autologous bone marrow transplantation in Hodgkin's disease. , 1985, Revue francaise de transfusion et immuno-hematologie.

[34]  G. Clamon,et al.  Salvage therapy of aggressive non‐Hodgkin's lymphoma with a combination of vinblastine, bleomycin, and cisplatin , 1984, Cancer.

[35]  F. Appelbaum,et al.  Review of the use of marrow transplantation in the treatment of non-Hodgkin's lymphoma. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Wheeler,et al.  Combination chemotherapy of refractory lymphoma with cis‐dichlorodiamineplatinum, vinblastine, and bleomycin , 1982, Cancer.

[37]  F. Cabanillas,et al.  IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. , 1982, Blood.

[38]  F. Cavalli,et al.  Phase II trial of cis‐dichlorodiammineplatinum (II) in advanced malignant lymphoma: A study of the cancer and acute leukemia group B , 1981 .

[39]  B. Barlogie,et al.  Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosine. , 1981, Cancer research.

[40]  F. Cavalli,et al.  Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B. , 1981, Cancer.

[41]  C. Coltman,et al.  Phase II evaluation of cis-dichlorodiammineplatinum(II) in lymphomas: a Southwest Oncology Group Study. , 1979, Cancer treatment reports.

[42]  K. Lennert,et al.  The Histopathology of Malignant Lymphoma , 1975 .

[43]  J. Peto,et al.  Asymptotically Efficient Rank Invariant Test Procedures , 1972 .

[44]  R. Peto,et al.  Asymptotically efficient rank invariant test procedure (with discussion). , 1972 .

[45]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .